$PFE

Will be interesting to see data on Ki67 with regards to Ibrance aka palbociclib | story isn’t over yet!!

Also high vs intermediate risk groups.

Can’t wait to see Penelope-B data as that’s the high-risk adj group vs high and intermediate group for PALLAS. 

Too early.